Shots:
- Gilead has reported final P-III (MYR301) trial data assessing bulevirtide (QD) for 144wks. in 150 pts living with HDV, who were randomized to either bulevirtide (2mg, n=49 or 10mg, n=50) or no antiviral therapy arm (n=51); pts in no therapy arm were switched to 10mg after 48wks.
- In the trial, 36% adults (23/64) with chronic HDV maintained virologic suppression for ~2yrs. after stopping treatment, following undetectable HDV RNA at EOT. Pts who maintained undetectable HDV RNA for 1yr. after treatment had no relapses in 2yr.
- 90% pts (9/10) who were undetectable for ≥96wks. during treatment showed sustained effects off-therapy; data was presented at EASL 2025
Ref: Businesswire | Image: Gilead
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
